Biosimilar Insulins (Generally) Won't Need Comparative Clinical Immunogenicity Data, US FDA Says

 
• By Michael Cipriano
  
insulin hormone vials-single use syringe_1200x675
The US FDA is proposing streamlining development of biosimilar/interchangeable insulins.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics